Nkarta (NKTX) Competitors $1.43 -0.12 (-7.74%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.46 +0.04 (+2.45%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. ZVRA, DNA, ORKA, PRTC, SLDB, GLUE, ERAS, MREO, SNDL, and TRDAShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Zevra Therapeutics (ZVRA), Ginkgo Bioworks (DNA), Oruka Therapeutics (ORKA), PureTech Health (PRTC), Solid Biosciences (SLDB), Monte Rosa Therapeutics (GLUE), Erasca (ERAS), Mereo BioPharma Group (MREO), SNDL (SNDL), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Zevra Therapeutics Ginkgo Bioworks Oruka Therapeutics PureTech Health Solid Biosciences Monte Rosa Therapeutics Erasca Mereo BioPharma Group SNDL Entrada Therapeutics Zevra Therapeutics (NASDAQ:ZVRA) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is ZVRA or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Nkarta's return on equity of -27.13% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-342.63% -159.54% -51.50% Nkarta N/A -27.13%-21.67% Does the MarketBeat Community prefer ZVRA or NKTX? Nkarta received 24 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 94.74% of users gave Zevra Therapeutics an outperform vote while only 76.92% of users gave Nkarta an outperform vote. CompanyUnderperformOutperformZevra TherapeuticsOutperform Votes3694.74% Underperform Votes25.26%NkartaOutperform Votes6076.92% Underperform Votes1823.08% Which has higher valuation and earnings, ZVRA or NKTX? Zevra Therapeutics has higher revenue and earnings than Nkarta. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M18.68-$46.05M-$2.24-3.64NkartaN/AN/A-$117.50M-$1.88-0.76 Does the media refer more to ZVRA or NKTX? In the previous week, Zevra Therapeutics had 7 more articles in the media than Nkarta. MarketBeat recorded 8 mentions for Zevra Therapeutics and 1 mentions for Nkarta. Zevra Therapeutics' average media sentiment score of 0.33 beat Nkarta's score of -0.67 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Zevra Therapeutics Neutral Nkarta Negative Do insiders & institutionals believe in ZVRA or NKTX? 35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 8.7% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ZVRA or NKTX? Zevra Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Do analysts prefer ZVRA or NKTX? Zevra Therapeutics currently has a consensus target price of $22.29, indicating a potential upside of 173.44%. Nkarta has a consensus target price of $15.00, indicating a potential upside of 948.95%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 SummaryNkarta beats Zevra Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.91M$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.767.2324.5519.25Price / SalesN/A230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book0.266.617.064.46Net Income-$117.50M$142.13M$3.19B$247.07M7 Day Performance-6.54%2.79%1.49%3.05%1 Month Performance-23.94%2.70%5.87%-2.85%1 Year Performance-86.37%-4.42%14.94%4.63% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.2972 of 5 stars$1.43-7.7%$15.00+949.0%-86.4%$100.91MN/A-0.76140Upcoming EarningsZVRAZevra Therapeutics2.7885 of 5 stars$8.35+0.5%$22.14+165.2%+44.5%$451.87M$23.61M-4.2420DNAGinkgo Bioworks0.5417 of 5 stars$7.79+11.7%$4.58-41.2%N/A$451.80M$227.04M-0.601,218ORKAOruka Therapeutics3.2008 of 5 stars$11.89+7.2%$39.86+235.2%N/A$445.17MN/A-1.90N/APositive NewsPRTCPureTech Health2.0733 of 5 stars$17.99+3.1%$45.00+150.2%-40.7%$430.65M$3.33M0.00100News CoverageSLDBSolid Biosciences3.4174 of 5 stars$5.36+5.3%$15.67+192.3%-66.9%$415.36M$8.09M-1.76100GLUEMonte Rosa Therapeutics2.3794 of 5 stars$6.73+7.3%$15.25+126.6%-33.0%$413.47M$14.98M-3.6890Earnings ReportAnalyst RevisionERASErasca2.8866 of 5 stars$1.46+1.4%$4.90+235.6%-28.5%$412.78MN/A-1.76120Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMREOMereo BioPharma Group2.5106 of 5 stars$2.63+0.4%$7.83+197.8%-20.9%$408.03M$1M0.0040Earnings ReportPositive NewsSNDLSNDL2.8812 of 5 stars$1.55+2.6%$3.25+109.7%-11.0%$407.30M$911.22M-5.002,516TRDAEntrada Therapeutics2.8469 of 5 stars$10.81flat$25.67+137.4%-23.9%$406.40M$210.78M6.80110 Remove Ads Related Companies and Tools Related Companies Zevra Therapeutics Competitors Ginkgo Bioworks Competitors Oruka Therapeutics Competitors PureTech Health Competitors Solid Biosciences Competitors Monte Rosa Therapeutics Competitors Erasca Competitors Mereo BioPharma Group Competitors SNDL Competitors Entrada Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
